InflaRx N.V. (NASDAQ:IFRX) and AzurRx BioPharma Inc. (NASDAQ:AZRX) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx N.V.	N/A	0.00	N/A	-1.42	0.00
AzurRx BioPharma Inc.	N/A	0.00	11.99M	-0.88	0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows us InflaRx N.V. and AzurRx BioPharma Inc.’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
InflaRx N.V.	0.00%	-22.7%	-21.9%
AzurRx BioPharma Inc.	0.00%	-301.4%	-154.5%

Liquidity

The Current Ratio and a Quick Ratio of InflaRx N.V. are 18.7 and 18.7. Competitively, AzurRx BioPharma Inc. has 3.9 and 3.9 for Current and Quick Ratio. InflaRx N.V.’s better ability to pay short and long-term obligations than AzurRx BioPharma Inc.

Institutional and Insider Ownership

InflaRx N.V. and AzurRx BioPharma Inc. has shares held by institutional investors as follows: 58.8% and 19%. On the other hand, insiders held about 4.7% of AzurRx BioPharma Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
InflaRx N.V.	0.99%	-4.81%	-11.65%	-15.66%	63.49%	40.86%
AzurRx BioPharma Inc.	-5.13%	-17.04%	-29.66%	-42.19%	-38.54%	-49.14%

For the past year InflaRx N.V. had bullish trend while AzurRx BioPharma Inc. had bearish trend.

Summary

InflaRx N.V. beats on 5 of the 6 factors AzurRx BioPharma Inc.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.